

ESRA ITALIAN CHAPTER


309 NATIONAL MEETING

Presidents:

Giuseppe Servillo, Fabrizio Fattorini

13-15 NOV 2025

NAPOLI HOTEL RAMADA





W. Ciaschi

TRANSITIONAL PAIN SERVICE: MISSION POSSIBLE WITH NEW DRUGS?

UOC Anestesia - Rianimazione e Terapia Antalgica - Altissima Professionalità in Cure

Antalgiche - Servizio di Terapia Antalgica - Spoke II° Livello

Ospedale F. Spaziani - Frosinone



Il sottoscritto dichiara che negli ultimi due anni NON ha avuto rapporti di finanziamento con soggetti portatori di interessi commerciali in campo sanitario



INTRODUZIONE

Uncontrolled pain, readmission to hospital and persistent opioid use in patients discharged with complex pain reflect gaps in post-operative care.

10-20% of post-operative patients are discharged without appropriate specialist analgesic follow-up to manage their complex post-operative pain and adequately wean them from opioid drugs

These patients often seek re-prescription of medication, primary care and/or hospital admission.

Reducing persistent opioid use after surgery through the implementation of transitional pain medicine is a public health priority.



THE CURRENT STATE OF TREATMENT FOR PATIENTS WITH COMPLEX ACUTE POST SURGICAL PAIN

- Poorly controlled post-surgical pain is a risk factor for hospital readmission and increased use of healthcare resources.
- The development of CPSP
 (CHRONIC POSTSURGICAL PAIN) is
 thought to be the main factor
 determining the persistent use of
 opioids.



THE CURRENT STATE OF TREATMENT FOR PATIENTS WITH COMPLEX ACUTE POST-SURGICAL PAIN

Thoracic surgery

Limb Inguinal hernia repair

Mastectomy

Spinal surgery

Craniotomy

Arthroplasty

Hysterectomy

Younger age

Lower income

 Comorbidities (diabetes, heart failure)

 Preoperative medications (benzodiazepines, antidepressants)



THE CURRENT STATE OF TREATMENT FOR PATIENTS WITH COMPLEX ACUTE POST-SURGICAL PAIN

- The situation is much more serious for patients who take opioids before surgery.
- Opioid-dependent patients typically leave hospital with a 100–300% increase in their opioid dose compared to baseline after major surgery, usually without appropriate follow-up or a plan for gradual withdrawal.
- The use of high-dose opioids in this context is closely related to increased mortality.
- In all these cases, the incidence of CPSP ranges from 5% to 85%.



THE CURRENT STATE OF TREATMENT FOR PATIENTS WITH COMPLEX ACUTE POST-SURGICAL PAIN

- CPSP is considered a secondary disease and not just a symptom.
- Chronic post-surgical pain is defined as pain that develops or increases in intensity after surgical procedures or tissue damage and persists beyond the healing process for at least three months after the initial event.
- In addition, patients with CPSP have a lower quality of life regardless of opioid use.



- Anaesthetists
- Pain therapists
- Nurses
- Psychologists
- Physiotherapists trained in myofascial release
- Patient care coordinators





Working together to relieve pain



- Effective control of acute postoperative pain through the use of "multimodal analgesia" and judicious use of opioids with the aim of facilitating a reduction in post-operative opioid consumption.
- Non-pharmacological interventions such as physiotherapy.
- Psychological therapy based on pre-operative patient education, identifying patients at higher risk of developing CPSP






There are two subgroups of patients treated by TPS:

- **A-** Patients who have never taken opioids and who do not suffer from pre-existing pain have a 5-10% risk of developing moderate to severe CPSP.
- **B-** Patients who present for surgery with pre-existing pain and are undergoing pre-operative treatment with opioids.

These patients face "acute on chronic" post-operative pain. They typically leave hospital after a prolonged stay on higher doses of opioids than before admission. They continue their opioid regimen without a reduction plan and often with a new medication threshold.



TPS is structured around the perioperative continuum and continues to provide care to patients for up to 6 months after discharge.





In this way, TPS aims to bridge the gap between preoperative, hospital and outpatient care for patients undergoing surgery.

The usual fragmentation of postoperative pain management between surgeons, anaesthetists, pain nurses and general practitioners is replaced by TPS.



- Multimodal analgesia includes:
- non-opioid systemic analgesics such as paracetamol
- non-steroidal anti-inflammatory drugs (NSAIDs)
- gabapentinoids (pregabalin and gabapentin)
- infusions of local anaesthetics (intravenous lidocaine)
- ketamine infusion
- medical cannabis



- Many of these drugs can be administered in the period immediately prior to surgery as part of pre-emptive analgesia to help reduce opioid use in the perioperative period.
- By acting on different receptor families along the nociceptive pathway, the multimodal analgesic regimens used in TPS optimise pain control through synergistic pharmacological effects that result in opioid savings.



- **SUZETRIGINA** is a new non-opioid drug for the treatment of moderate to severe acute post-operative pain, approved by the FDA in the United States in 2025.
- It acts as a selective blocker of NaV1.8 sodium channels, which are involved in the transmission of pain signals from peripheral nociceptors to the central nervous system, and has a favourable safety profile, without the risk of addiction associated with opioids.



Side effects: itching, muscle spasms, increased creatine phosphokinase and skin rashes.

Contraindications: Concomitant use with potent CYP3A inhibitors is contraindicated and it is recommended to avoid grapefruit during treatment.





- Intravenous infusion of LIDOCAINE (2 mg/min > 70 kg; 1 mg/min < 70 kg) has proven to be a valuable analgesic adjuvant, leading to a reduction in post-operative pain and a lower use of opioids in the post-operative period.
- Lidocaine works by modulating pain signals and reducing inflammation in the body.



- **KETAMINE** (an NMDA antagonist) appears to be the pharmacological agent with the most positive and consistent preventive analgesic results. A comprehensive systematic review for the prevention of chronic pain after surgery in adults identified ketamine as the most reliable pharmacological agent for the prevention of CPSP.
- Low-dose ketamine infusions (i.e., 0.05–0.2 mg/kg/hour) administered outside the operating theatre to patients with pre-existing chronic pain conditions who typically take more than 80 mg of oral morphine equivalent per day in the post-operative setting did not result in any significant side effects for the patient.




- The liberal use of local-regional techniques including incision site infiltration, wound catheters and nerve blocks has been encouraged as part of multimodal analgesia.
- Single or continuous nerve blocks have proven particularly useful in limb surgery and are recommended for the management of acute postoperative pain.
- Similarly, central neuraxial blocks have been shown to have significant opioid-sparing effects following major abdominal, thoracic, and intraabdominal vascular surgery.
- Neuromodulation and/or cry neuromodulation techniques may be used.



NON-PHARMACOLOGICAL INTERVENTIONS: PHYSIOTHERAPY

- Prehabilitation is the process whereby patients with reduced functionality prior to surgery are provided with targeted interventions to improve their physical abilities before major elective surgery.
- It includes physiotherapy, nutritional support, patient education and specific muscle training.
- Pre-rehabilitation appears to improve postoperative outcomes and functional recovery, resulting in a reduction in hospital stay duration in adults undergoing major colorectal, thoracic and breast surgery.





PSYCHOLOGICAL THERAPY

- The psychological basis of chronic pain is well established. In fact, several psychological risk factors have been linked to the chronicity of acute postoperative pain.
- These include increased vulnerability to pain trauma, pain catastrophising, preoperative anxiety disorders, and negative affective states, including depression.
- Therefore, psychological preparation and therapy are another key component of TPS.





OUTPATIENT CARE

- Upon discharge, patients are presented with a personalised pain management plan.
- Patients are then monitored for a period of 3 to 6 months in order to assess pain progression and successfully discontinue opioid medication.
- At the end of TPS treatment, patients are transferred to their general practitioner.



CONCUSIONS

- The goal of the TPS is to make significant progress in reducing the incidence of CPSP and persistent opioid use using this new approach to perioperative care.
- Comprehensive programs that combine new preventive pharmacological strategies, pre-rehabilitation, mindfulness, cognitive-behavioral therapy, etc., could positively influence the long-term path of patients after major surgery by improving their quality of life and drastically reducing healthcare costs.